Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
J Clin Neurophysiol ; 40(6): 562-565, 2023 Sep 01.
Article in English | MEDLINE | ID: mdl-36893379

ABSTRACT

SUMMARY: A 30-year-old man with recurrent headaches and seizure-like activity and a 26-year-old woman with worsening headaches were admitted to the hospital. Both had ventriculoperitoneal shunts and history of several shunt revisions for congenital hydrocephalus. The ventricle size visualized on computed tomography scans was unremarkable, and shunt series were negative in both cases. Both patients began to present with brief periods of unresponsiveness, and video electroencephalography at that time showed periods of diffuse delta slowing. Lumbar punctures revealed increased opening pressures. Despite normal imaging and shunt series, both patients ultimately had increased intracranial pressure caused by shunt malfunction. This series demonstrates the difficulty of diagnosing potential transient increases in intracranial pressure based on standard-of-care diagnostics/examination and the potentially critical role for EEG in the identification of shunt malfunction.


Subject(s)
Hydrocephalus , Ventriculoperitoneal Shunt , Male , Female , Humans , Adult , Ventriculoperitoneal Shunt/adverse effects , Intracranial Pressure , Hydrocephalus/surgery , Headache , Electroencephalography
2.
Radiol Case Rep ; 17(6): 2220-2226, 2022 Jun.
Article in English | MEDLINE | ID: mdl-35496743

ABSTRACT

Cortical laminar necrosis usually occurs secondary to infarcts or hypoxia, however other causes, including hypoglycemia, status epilepticus and immunosuppressive therapy have been reported. To our knowledge, CLN is not a phenomenon expected in the case of trauma. We report a unique case of delayed post-traumatic CLN which occurred 30 days after the initial trauma, without any proven cause apart from possible spreading depolarization induced spreading ischemia from adjacent subarachnoid hemorrhage with distinct radiologic features.

3.
Neurologist ; 26(2): 69-72, 2021 Mar 04.
Article in English | MEDLINE | ID: mdl-33646993

ABSTRACT

INTRODUCTION: Creutzfeldt-Jakob disease (CJD) is a prion protein disorder of significant consequence and currently incurable. Diagnosis can be challenging early in the disease course. CJD can present in many ways but often fits a pattern of cognitive problems, cerebellar disturbance, behavioral/psychological changes, and perhaps myoclonus. CASE REPORT: We herein present the case of a 69-year-old White male with subacute progressive bulbar and limb weakness over ten weeks period. Early on, he was diagnosed with amyotrophic lateral sclerosis versus autoimmune-related bulbar neuropathy and treated as such. However, he continued to deteriorate clinically that prompted another admission, upon readmission, his cerebrospinal fluid RTQuick and 14-3-3 from the National Prion Disease Pathology Surveillance Center (NPDPSC) did eventually return positive. Hence he was diagnosed with CJD. CONCLUSIONS: CJD may present with progressive bulbar symptoms similar to acute inflammatory demyelinating polyradiculoneuropathy (MF variant), motor neuron disease, or autoimmune brainstem encephalitis. It becomes even higher on the differentials especially with no response to immunotherapy.


Subject(s)
Creutzfeldt-Jakob Syndrome , Encephalitis , Myoclonus , Aged , Brain , Creutzfeldt-Jakob Syndrome/diagnosis , Disease Progression , Humans , Male
4.
J Neurol ; 267(11): 3135-3153, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32561990

ABSTRACT

BACKGROUND: In December 2019, unexplained cases of pneumonia emerged in Wuhan, China, which were found to be secondary to the novel coronavirus SARS-CoV-2. On March 11, 2020, the WHO declared the Coronavirus Disease 2019 (COVID-2019) outbreak, a pandemic. OBJECTIVE: To clarify the neurological complications of SARS-CoV-2 infection including the potential mechanisms and therapeutic options. METHODS: We conducted a systematic literature search from December 01, 2019 to May 14, 2020 using multiple combinations of keywords from PubMed and Ovid Medline databases according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We included articles with cases of COVID-19 where neurological involvement was evident. RESULTS: We were able to identify 82 cases of COVID-19 with neurological complications. The mean age was 62.3 years. 37.8% of the patients were women (n = 31). 48.8% of the patients (n = 40) had cerebrovascular insults, 28% (n = 23) had neuromuscular disorders, and 23% of the patients (n = 19) had encephalitis or encephalopathy. CONCLUSIONS: Neurological manifestations of COVID-19 are not rare, especially large vessel stroke, Guillain-Barre syndrome, and meningoencephalitis. Moving forward, further studies are needed to clarify the prevalence of the neurological complications of SARS-CoV-2 infection, investigate their biological backgrounds, and test treatment options. Physicians should be cautious not to overlook other neurological diagnoses that can mimic COVID-19 during the pandemic.


Subject(s)
Coronavirus Infections/complications , Nervous System Diseases/epidemiology , Nervous System Diseases/virology , Pneumonia, Viral/complications , Adult , Aged , Betacoronavirus , COVID-19 , Female , Humans , Male , Middle Aged , Pandemics , Prevalence , SARS-CoV-2
6.
Stroke ; 50(4): 995-998, 2019 04.
Article in English | MEDLINE | ID: mdl-30879436

ABSTRACT

Background and Purpose- Sulfonylurea medications have been linked to reduced brain edema and improved outcome following ischemic stroke, but their effects on primary intracerebral hemorrhage (pICH) have not been thoroughly explored. Increasing ICH volume and perihematomal edema (PHE) volume are predictors of poor outcome in pICH. We investigated whether preexisting sulfonylurea use influenced ICH volume, PHE volume, and discharge disposition in patients with type 2 diabetes mellitus presenting with pICH. Methods- We performed a retrospective chart review of all diabetic patients presenting with pICH to 2 tertiary academic centers from 2006 to 2016. All patients with diabetes mellitus, pICH, admission computed tomography scan, and sulfonylurea use on admission were included in our study. For each case, 2-matched controls (admission date, age, hematoma location [deep versus lobar], use of antiplatelet, or anticoagulant) with diabetes mellitus and pICH were consecutively selected. ICH and PHE volumes were measured via region of interest analysis on admission computed tomography. To mitigate the influence of ICH volume on PHE, the PHE/ICH surface area ratio was calculated. Hospital discharge disposition was determined via chart abstraction. We used the Wilcoxon rank-sum test and Fisher exact test to compare cases and controls. Results- Of 317 patients screened, 21 sulfonylurea cases and 42-matched controls met criteria for study inclusion. Sulfonylurea cases had significantly lower admission ICH volumes (median, 4 mL; interquartile range [IQR], 2-30 versus median, 25 mL; IQR, 6-60; P=0.011), PHE volumes (median, 4 mL; IQR, 0.9-24 versus median, 17; IQR, 6-37; P=0.0095), and PHE/ICH surface area ratios (median, 0.28; IQR, 0.1-0.4 versus median, 0.43; IQR, 0.3-0.6; P=0.013) as compared with controls. Sulfonylureas were associated with improved discharge disposition ( P=0.0062). Conclusions- In patients with diabetes mellitus and pICH, sulfonylurea use predicted lower ICH and PHE volumes, lower relative PHE, and improved discharge disposition. Given the paucity of treatment options for pICH, further study of sulfonylureas is warranted.


Subject(s)
Brain Edema/diagnostic imaging , Brain/diagnostic imaging , Cerebral Hemorrhage/diagnostic imaging , Diabetes Mellitus, Type 2/drug therapy , Sulfonylurea Compounds/therapeutic use , Aged , Aged, 80 and over , Brain Edema/complications , Case-Control Studies , Cerebral Hemorrhage/complications , Diabetes Mellitus, Type 2/complications , Female , Humans , Male , Middle Aged , Retrospective Studies , Severity of Illness Index , Tomography, X-Ray Computed
7.
J Peripher Nerv Syst ; 23(2): 129-133, 2018 06.
Article in English | MEDLINE | ID: mdl-29696771

ABSTRACT

Peripheral neuropathy is a common side effect of many chemotherapeutic agents including paclitaxel. We prospectively evaluated demographic and laboratory data in a cohort of 61 woman with breast cancer prior to paclitaxel exposure to explore factors that predispose to neuropathy development. Neuropathy was graded based on the total neuropathy score reduced version (rTNS) at baseline and at 4 months after initiation of chemotherapy. A multivariate analysis identified predictors with the strongest association with a change in rTNS. Serum albumin (P = .002), paclitaxel dose (P = .001), and body surface area (P = .006) were statistically significantly associated with a positive rTNS change (worsening neuropathy). These results suggest that poor nutritional status and obesity increase the risk of paclitaxel induced neuropathy, and that screening for these factors prior to chemotherapy exposure may improve early neuropathy detection or decrease risk with dietary modifications.


Subject(s)
Antineoplastic Agents, Phytogenic/adverse effects , Breast Neoplasms/drug therapy , Paclitaxel/adverse effects , Peripheral Nervous System Diseases/chemically induced , Adult , Aged , Antineoplastic Agents, Phytogenic/therapeutic use , Female , Humans , Middle Aged , Paclitaxel/therapeutic use , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...